(Date:5/20/2008)...Ambulatory Services of,America, Inc. announced the...t venture to provide outpatient radiation oncology...en Denton Cancer Center, LP and ASA,s,subsidiary, ...of Denton,will own and operate a radiation therapy...ed and operated by Denton Cancer Center., (Logo: ...
(Date:5/20/2008)... out-patient procedures at no c...., May 20 /PRNewswire/ -- Compass Clinical Researc...rancisco Bay Area (RSC) are,hoping to recruit betw...build-up of fluid in the fallopian tubes that can ...part of a study of the effectiveness of a new,out-...
(Date:5/20/2008)...d Fat - and with Omega-3, PARAMUS, N.J., May 20 /...q: SMBL ) has launched Smart Balance(R) Butter Bl...Blend Sticks are 50 percent real butter,and 50 per...lance(R) Butter,Blend Sticks are offered in a conv...ealthier and tasty alternative for use in cooking,...
(Date:5/20/2008)... survival, researchers say. , , TUESDAY...ysis for patients with acute kidney injury does no... the rate of organ failure, a new study finds. ,... in critically ill patients. Approximately 2 perce...ercent of critically ill patients, will suffer fro...
Breaking Medicine News(10 mins):Health News:Ambulatory Services of America, Inc. Announces Joint Venture With Denton Cancer Center, LP 2Health News:Research Grant to Fund Free Surgeries for Women Suffering From Blocked Fallopian Tubes 2Health News:Research Grant to Fund Free Surgeries for Women Suffering From Blocked Fallopian Tubes 3Health News:New Smart Balance(R) Butter Blend Sticks Make Healthier Cooking & Baking Easy 2Health News:More Dialysis Not Better in Acute Kidney Injury 2(Date:5/19/2008)... May 19 /- Helix Health, the first U....ng a 90-minute webcast this,Wednesday, May 21, 200... Medicine Is Changing the Management of Breast & O...re, http://event.netbriefings.com/event/helixhealt... United States are diagnosed with cancer.,There is...
(Date:5/19/2008)...Be Presented at the 2008 Annual European Congress ...Against Rheumatism (EULAR) -, - Initiation of Pha... of 2008 -, SAN D...iences, Inc.,(Nasdaq: RDEA ) today announced the ...or the treatment of patients with gout, RDEA594. G...
(Date:5/19/2008)...egulatory equivalent filing anticipated in 1Q 2009.../ -- Pharmasset, Inc.,(Nasdaq: VRUS ) has nominat...e treatment of chronic hepatitis C virus (HCV). PS...rase inhibitor of HCV that is being advanced into,...dies required for,submission of an Investigational...
(Date:5/18/2008)...ve Disease Week data highlight effects of AMITIZA ...SAN DIEGO, May 18 /- New study result...ostone) 8 mcg lead to significant relief,of overal...pation (IBS-C).,These results were presented at Di...l international meeting of digestive disease speci...
Breaking Medicine Technology:Join NPR's David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 2Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 2New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 4New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 5New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 6New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 7Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 1Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 2Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 3Scientists discover tiny RNAs play a big role in controlling genes 4578 1Food restriction increases dopamine receptor levels in obese rats 4575 1Food restriction increases dopamine receptor levels in obese rats 4575 2Food restriction increases dopamine receptor levels in obese rats 4575 3The new source of islet cells 4571 1...NCETON, N.J.--(BUSINESS WIRE)--Jun 28, 2007 - Cyto...ta from a Phase 1,dose escalation study evaluating...n) in combination with bortezomib (Velcade(R),Mil...lapsed,multiple myeloma. Data from 33 patients wer...al of Bortezomib (Vel) and Samarium,(Sam) in Multi...
..., Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM...e presentation of two,posters at the XIth Annual I...reece from June 25-28th, 2007. The meeting highlig...atment of multiple,myeloma. ZIOPHARM is presenting...data that further elucidates its unique,mechanism ...
Other Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 2ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 3ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 4...ists steerable guidewires across difficult lesions...eter offers a low profile (3F-4F) and is compatibl... crossing difficult occlusions. Once the occlusio...guidewire position and an angioplasty balloon is d...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system.
The new XVG catheter is our highest power thrombectomy catheter designed for accessing distal anatomy. Utilizing proprietary Cross-Stream water jet technology, the XVG catheter removes thrombus quick
...copic navigation system that tracks multiple intra...d Wittkampf, Ph.D., and is being developed by Surg...,The LocaLisa system uses three skin electrode p...art to track catheters. Using a reference electrod...
Medicine Products: